<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03234751</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 1081082</org_study_id>
    <nct_id>NCT03234751</nct_id>
  </id_info>
  <brief_title>Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects</brief_title>
  <acronym>BNP3</acronym>
  <official_title>Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdventHealth Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AdventHealth Translational Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effects of nesiritide to placebo administered by a&#xD;
      continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy,&#xD;
      obese, insulin resistant individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2017</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is prospective randomized, double masked, 2-period cross over design, proof of concept study of the effects of intravenously administered rhBNP (nesiritide) on insulin sensitivity in otherwise healthy obese nondiabetic insulin resistant subjects.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IV infusion of nesiritide at a 3pmol/kg rate</measure>
    <time_frame>48 hours</time_frame>
    <description>Average changes in glucose disposal rates (GDR) and endogenous glucose production (EGP) from baseline corrected for body weight at steady state of the clamp during the high- and low-dose portions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV nesiritide 3 pmol/kg/min or placebo for nesiritide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV nesiritide 2 pmol/kg/min or placebo for nesiritide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continous IV infusion of Nesiritide</intervention_name>
    <description>Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.</description>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel A</arm_group_label>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperinsulinemic euglycemic clamp</intervention_name>
    <description>48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.</description>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel A</arm_group_label>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>48 hours of placebo.</description>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel A</arm_group_label>
    <arm_group_label>Obese nondiabetic insulin resistant subjects- Panel B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 40-65 years inclusive&#xD;
&#xD;
          2. Men and women&#xD;
&#xD;
          3. Able to provide written, informed consent&#xD;
&#xD;
          4. Weight stable (± 3 kg) during the 3 months prior to enrollment&#xD;
&#xD;
          5. BMI ≥ 30 kg/m2; body weight ≤ 106 kg&#xD;
&#xD;
          6. Resting blood pressure ≥ 110/60 mmHg and ≤ 150/100 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known coronary artery disease, angina or heart failure&#xD;
&#xD;
          2. Type 1 or Type 2 Diabetes (A1c ≥ 6.5% and/or fasting plasma glucose &gt;125mg/dL)&#xD;
&#xD;
          3. Bleeding disorders&#xD;
&#xD;
          4. Hemoglobin level &lt; 12.5 g/dL for women; &lt; 13.0 g/dL for men&#xD;
&#xD;
          5. Acute or chronic infections&#xD;
&#xD;
          6. Hepatitis and/or cirrhosis (AST or Alanine Aminotransferase 2.5 times upper limit of&#xD;
             normal)&#xD;
&#xD;
          7. Severe asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
          8. Renal insufficiency (creatinine &gt; 1.6 mg/dL)&#xD;
&#xD;
          9. Prior bariatric surgery&#xD;
&#xD;
         10. Inflammatory bowel disease or malabsorption&#xD;
&#xD;
         11. Cancer within the last 3 years (except non-melanoma skin cancer or treated cervical&#xD;
             carcinoma in situ)&#xD;
&#xD;
         12. Psychiatric or eating disorders&#xD;
&#xD;
         13. Untreated or inadequately controlled thyroid (abnormal TSH) or other endocrine&#xD;
             disorders&#xD;
&#xD;
         14. Active rheumatoid arthritis or other inflammatory rheumatic disorder&#xD;
&#xD;
         15. Pregnant or nursing women&#xD;
&#xD;
         16. Presence of clinically significant abnormalities on electrocardiogram&#xD;
&#xD;
         17. Smoking (within the last 3 months)&#xD;
&#xD;
         18. Known hypersensitivity to nesiritide or any of its excipients&#xD;
&#xD;
         19. Poor intravenous access&#xD;
&#xD;
         20. Use of medications: a) nitrates, b) beta-blockers, c) digoxin, d) anti-diabetic&#xD;
             agents, e) oral, injected or chronic topical steroids (inhaled steroids for mild&#xD;
             asthma are acceptable), f) chronic use of aspirin or other non-steroidal&#xD;
             anti-inflammatory drugs, including cyclooxygenase-2 inhibitors, g) other drugs known&#xD;
             to affect immune or metabolic function and h) orlistat, phenteramine or other weight&#xD;
             loss or anorectic agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Pratley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Reseach institute for Metabolism and Diabetes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). State-specific prevalence of obesity among adults--United States, 2007. MMWR Morb Mortal Wkly Rep. 2008 Jul 18;57(28):765-8.</citation>
    <PMID>18636063</PMID>
  </reference>
  <reference>
    <citation>Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. doi: 10.1161/CIRCULATIONAHA.106.171016. Epub 2005 Dec 27.</citation>
    <PMID>16380542</PMID>
  </reference>
  <reference>
    <citation>Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004 Jun;89(6):2522-5. doi: 10.1210/jc.2004-0288.</citation>
    <PMID>15181019</PMID>
  </reference>
  <reference>
    <citation>Aneja A, El-Atat F, McFarlane SI, Sowers JR. Hypertension and obesity. Recent Prog Horm Res. 2004;59:169-205. doi: 10.1210/rp.59.1.169.</citation>
    <PMID>14749502</PMID>
  </reference>
  <reference>
    <citation>Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007 May;25(5):909-20. doi: 10.1097/HJH.0b013e328048d004.</citation>
    <PMID>17414649</PMID>
  </reference>
  <reference>
    <citation>Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999 Jul;7(4):355-62. doi: 10.1002/j.1550-8528.1999.tb00418.x.</citation>
    <PMID>10440591</PMID>
  </reference>
  <reference>
    <citation>Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996 Oct;19(9):581-5. doi: 10.1007/BF03349021.</citation>
    <PMID>8957740</PMID>
  </reference>
  <reference>
    <citation>Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004 Feb 10;109(5):594-600. doi: 10.1161/01.CIR.0000112582.16683.EA.</citation>
    <PMID>14769680</PMID>
  </reference>
  <reference>
    <citation>Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006 Feb;27(1):47-72. doi: 10.1210/er.2005-0014. Epub 2005 Nov 16.</citation>
    <PMID>16291870</PMID>
  </reference>
  <reference>
    <citation>Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS, Vasan RS, Melander O, Wang TJ. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011 Oct;96(10):3242-9. doi: 10.1210/jc.2011-1182. Epub 2011 Aug 17.</citation>
    <PMID>21849523</PMID>
  </reference>
  <reference>
    <citation>Chen-Tournoux A, Khan AM, Baggish AL, Castro VM, Semigran MJ, McCabe EL, Moukarbel G, Reingold J, Durrani S, Lewis GD, Newton-Cheh C, Scherrer-Crosbie M, Kaplan LM, Wang TJ. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol. 2010 Nov 15;106(10):1450-5. doi: 10.1016/j.amjcard.2010.06.076.</citation>
    <PMID>21059435</PMID>
  </reference>
  <reference>
    <citation>Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA; Brain Natriuretic Peptide Subgroup of the Look AHEAD Research Group. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012 Jul;20(7):1511-8. doi: 10.1038/oby.2011.296. Epub 2011 Sep 29.</citation>
    <PMID>21959345</PMID>
  </reference>
  <reference>
    <citation>Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009 Jun 2;53(22):2070-7. doi: 10.1016/j.jacc.2009.02.038.</citation>
    <PMID>19477358</PMID>
  </reference>
  <reference>
    <citation>Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, Nikiforova VJ, Bergmann A, Kruse M, Seltmann AC, Bluher M, Pfeiffer AF, Rudovich N. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab. 2012 May;97(5):E731-9. doi: 10.1210/jc.2011-2839. Epub 2012 Mar 14.</citation>
    <PMID>22419733</PMID>
  </reference>
  <reference>
    <citation>Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T, Nakao K. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009 Dec;58(12):2880-92. doi: 10.2337/db09-0393. Epub 2009 Aug 18.</citation>
    <PMID>19690065</PMID>
  </reference>
  <reference>
    <citation>Heinisch BB, Vila G, Resl M, Riedl M, Dieplinger B, Mueller T, Luger A, Pacini G, Clodi M. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia. 2012 May;55(5):1400-5. doi: 10.1007/s00125-011-2392-1. Epub 2011 Dec 13.</citation>
    <PMID>22159910</PMID>
  </reference>
  <reference>
    <citation>Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012 Mar;122(3):1022-36. doi: 10.1172/JCI59701. Epub 2012 Feb 6. Erratum In: J Clin Invest. 2012 Apr 2;122(4):1584.</citation>
    <PMID>22307324</PMID>
  </reference>
  <reference>
    <citation>Plante E, Menaouar A, Danalache BA, Broderick TL, Jankowski M, Gutkowska J. Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. Diabetologia. 2014 Jun;57(6):1257-67. doi: 10.1007/s00125-014-3201-4. Epub 2014 Mar 5.</citation>
    <PMID>24595856</PMID>
  </reference>
  <reference>
    <citation>Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE. Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Curr Ther Res Clin Exp. 2015 Aug 14;77:83-9. doi: 10.1016/j.curtheres.2015.08.001. eCollection 2015 Dec.</citation>
    <PMID>26543510</PMID>
  </reference>
  <reference>
    <citation>Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993 Jan;76(1):91-6. doi: 10.1210/jcem.76.1.8380606.</citation>
    <PMID>8380606</PMID>
  </reference>
  <reference>
    <citation>Vila G, Grimm G, Resl M, Heinisch B, Einwallner E, Esterbauer H, Dieplinger B, Mueller T, Luger A, Clodi M. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes. 2012 Oct;61(10):2592-6. doi: 10.2337/db11-1466. Epub 2012 Jun 14.</citation>
    <PMID>22698919</PMID>
  </reference>
  <reference>
    <citation>Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J Obes (Lond). 2007 Feb;31(2):213-20. doi: 10.1038/sj.ijo.0803355. Epub 2006 Jun 6.</citation>
    <PMID>16755284</PMID>
  </reference>
  <reference>
    <citation>Timar R, Timar B, Degeratu D, Serafinceanu C, Oancea C. Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus. J Int Med Res. 2014 Oct;42(5):1131-8. doi: 10.1177/0300060514541829. Epub 2014 Jul 22.</citation>
    <PMID>25053801</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human B-type natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03234751
org study id: TRIMDFH 1081082
nct id: NCT03234751
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
is us export: No
The purpose of the study is to compare the effects of nesiritide to placebo administered by a
      continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy,
      obese, insulin resistant individuals.
allocation: Randomized
intervention model: Crossover Assignment
intervention model description: This study is prospective randomized, double masked, 2-period cross over design, proof of concept study of the effects of intravenously administered rhBNP (nesiritide) on insulin sensitivity in otherwise healthy obese nondiabetic insulin resistant subjects.
primary purpose: Basic Science
masking: Double (Participant, Investigator)
measure: IV infusion of nesiritide at a 3pmol/kg rate
time frame: 48 hours
description: Average changes in glucose disposal rates (GDR) and endogenous glucose production (EGP) from baseline corrected for body weight at steady state of the clamp during the high- and low-dose portions.
arm group label: Obese nondiabetic insulin resistant subjects- Panel A
arm group type: Active Comparator
description: IV nesiritide 3 pmol/kg/min or placebo for nesiritide
arm group label: Obese nondiabetic insulin resistant subjects- Panel B
arm group type: Active Comparator
description: IV nesiritide 2 pmol/kg/min or placebo for nesiritide
intervention type: Drug
intervention name: Continous IV infusion of Nesiritide
description: Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
arm group label: Obese nondiabetic insulin resistant subjects- Panel A
arm group label: Obese nondiabetic insulin resistant subjects- Panel B
intervention type: Drug
intervention name: Hyperinsulinemic euglycemic clamp
description: 48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
arm group label: Obese nondiabetic insulin resistant subjects- Panel A
arm group label: Obese nondiabetic insulin resistant subjects- Panel B
intervention type: Drug
intervention name: Placebo
description: 48 hours of placebo.
arm group label: Obese nondiabetic insulin resistant subjects- Panel A
arm group label: Obese nondiabetic insulin resistant subjects- Panel B
criteria: 
gender: All
minimum age: 40 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Richard Pratley, MD
role: Principal Investigator
affiliation: Translational Reseach institute for Metabolism and Diabetes
facility: 
country: United States
citation: Centers for Disease Control and Prevention (CDC). State-specific prevalence of obesity among adults--United States, 2007. MMWR Morb Mortal Wkly Rep. 2008 Jul 18;57(28):765-8.
PMID: 18636063
citation: Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. doi: 10.1161/CIRCULATIONAHA.106.171016. Epub 2005 Dec 27.
PMID: 16380542
citation: Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004 Jun;89(6):2522-5. doi: 10.1210/jc.2004-0288.
PMID: 15181019
citation: Aneja A, El-Atat F, McFarlane SI, Sowers JR. Hypertension and obesity. Recent Prog Horm Res. 2004;59:169-205. doi: 10.1210/rp.59.1.169.
PMID: 14749502
citation: Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007 May;25(5):909-20. doi: 10.1097/HJH.0b013e328048d004.
PMID: 17414649
citation: Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999 Jul;7(4):355-62. doi: 10.1002/j.1550-8528.1999.tb00418.x.
PMID: 10440591
citation: Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996 Oct;19(9):581-5. doi: 10.1007/BF03349021.
PMID: 8957740
citation: Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004 Feb 10;109(5):594-600. doi: 10.1161/01.CIR.0000112582.16683.EA.
PMID: 14769680
citation: Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006 Feb;27(1):47-72. doi: 10.1210/er.2005-0014. Epub 2005 Nov 16.
PMID: 16291870
citation: Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS, Vasan RS, Melander O, Wang TJ. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011 Oct;96(10):3242-9. doi: 10.1210/jc.2011-1182. Epub 2011 Aug 17.
PMID: 21849523
citation: Chen-Tournoux A, Khan AM, Baggish AL, Castro VM, Semigran MJ, McCabe EL, Moukarbel G, Reingold J, Durrani S, Lewis GD, Newton-Cheh C, Scherrer-Crosbie M, Kaplan LM, Wang TJ. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol. 2010 Nov 15;106(10):1450-5. doi: 10.1016/j.amjcard.2010.06.076.
PMID: 21059435
citation: Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA; Brain Natriuretic Peptide Subgroup of the Look AHEAD Research Group. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012 Jul;20(7):1511-8. doi: 10.1038/oby.2011.296. Epub 2011 Sep 29.
PMID: 21959345
citation: Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009 Jun 2;53(22):2070-7. doi: 10.1016/j.jacc.2009.02.038.
PMID: 19477358
citation: Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, Haddad I, Nikiforova VJ, Bergmann A, Kruse M, Seltmann AC, Bluher M, Pfeiffer AF, Rudovich N. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab. 2012 May;97(5):E731-9. doi: 10.1210/jc.2011-2839. Epub 2012 Mar 14.
PMID: 22419733
citation: Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T, Nakao K. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009 Dec;58(12):2880-92. doi: 10.2337/db09-0393. Epub 2009 Aug 18.
PMID: 19690065
citation: Heinisch BB, Vila G, Resl M, Riedl M, Dieplinger B, Mueller T, Luger A, Pacini G, Clodi M. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia. 2012 May;55(5):1400-5. doi: 10.1007/s00125-011-2392-1. Epub 2011 Dec 13.
PMID: 22159910
citation: Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012 Mar;122(3):1022-36. doi: 10.1172/JCI59701. Epub 2012 Feb 6. Erratum In: J Clin Invest. 2012 Apr 2;122(4):1584.
PMID: 22307324
citation: Plante E, Menaouar A, Danalache BA, Broderick TL, Jankowski M, Gutkowska J. Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice. Diabetologia. 2014 Jun;57(6):1257-67. doi: 10.1007/s00125-014-3201-4. Epub 2014 Mar 5.
PMID: 24595856
citation: Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE. Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Curr Ther Res Clin Exp. 2015 Aug 14;77:83-9. doi: 10.1016/j.curtheres.2015.08.001. eCollection 2015 Dec.
PMID: 26543510
citation: Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993 Jan;76(1):91-6. doi: 10.1210/jcem.76.1.8380606.
PMID: 8380606
citation: Vila G, Grimm G, Resl M, Heinisch B, Einwallner E, Esterbauer H, Dieplinger B, Mueller T, Luger A, Clodi M. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes. 2012 Oct;61(10):2592-6. doi: 10.2337/db11-1466. Epub 2012 Jun 14.
PMID: 22698919
citation: Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J Obes (Lond). 2007 Feb;31(2):213-20. doi: 10.1038/sj.ijo.0803355. Epub 2006 Jun 6.
PMID: 16755284
citation: Timar R, Timar B, Degeratu D, Serafinceanu C, Oancea C. Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus. J Int Med Res. 2014 Oct;42(5):1131-8. doi: 10.1177/0300060514541829. Epub 2014 Jul 22.
PMID: 25053801
responsible party type: Sponsor
mesh term: Insulin Resistance
mesh term: Natriuretic Peptide, Brain
sharing ipd: No